Atirmociclib Reduces Progression Risk by 40% in CDK4/6-Pretreated Metastatic Breast Cancer

The Phase 2 FOURLIGHT-1 trial shows that atirmociclib plus fulvestrant significantly improves progression-free survival in HR+, HER2- metastatic breast cancer after CDK4/6 inhibitors, reducing progression or death risk by 40%. Benefits were consistent across subgroups, with a manageable safety profile and low discontinuation rate (6.4%), supporting development in earlier treatment settings.

Pfizer has reported positive topline results from the Phase 2 FOURLIGHT-1 trial, highlighting the potential of atirmociclib, a next-generation, selective CDK4 inhibitor, in patients with hormone receptor positive, HER2-negative advanced or metastatic breast cancer previously treated with CDK4/6 inhibitors.

The randomized, open-label study met its primary endpoint, demonstrating a statistically significant improvement in progression-free survival. Atirmociclib combined with fulvestrant reduced the risk of disease progression or death by 40% compared with control arms, corresponding to a hazard ratio of 0.60, 95% CI 0.440 to 0.825, p=0.0007. Notably, efficacy was consistent across all prespecified subgroups, including patients with visceral disease, differing menopausal status, and varying durations of prior CDK4/6 inhibitor exposure.

The study enrolled 264 patients across 14 countries, all of whom had experienced disease progression following prior CDK4/6 inhibitor-based therapy. More than 90% initiated atirmociclib within three months of their last CDK4/6 inhibitor, reflecting a population with early resistance, a setting associated with limited therapeutic options and poor prognosis.

“These results are especially encouraging given that the FOURLIGHT‑1 study enrolled patients whose disease had progressed soon after prior CDK4/6 inhibitor therapy, a difficult-to-treat population,” said Jeff Legos, Chief Oncology Officer, Pfizer. “The strength of these data reinforces our confidence that atirmociclib may meaningfully differentiate from the CDK4/6 inhibitor class, the standard-of-care backbone in HR-positive breast cancer, with the potential for improved efficacy and tolerability. We are continuing to accelerate development of this next-generation cell cycle inhibitor in earlier lines of therapy where it may offer even greater benefit for patients.”

From a safety perspective, atirmociclib demonstrated a manageable and well-tolerated profile. Treatment discontinuation due to adverse events occurred in 6.4% of patients, with no new safety signals observed. The safety findings were consistent with earlier studies, supporting continued development.

Overall survival data remain immature, with approximately 20% of events reported at the time of analysis. Additional endpoints, including objective response and duration of response, are expected to provide further context once fully evaluated.

Atirmociclib represents a selective CDK4-targeting approach targeting CDK4 specifically, a key regulator of cell cycle progression. Unlike currently approved CDK4/6 inhibitors, selective CDK4 inhibition may offer a differentiated efficacy and tolerability profile, particularly in patients who develop resistance to earlier therapies.

These Phase 2 findings support Pfizer’s broader strategy to position atirmociclib earlier in the treatment continuum. A Phase 3 registrational trial in the first-line metastatic setting is ongoing, and results from a neoadjuvant Phase 2 study in early breast cancer are anticipated.